Key Dates

Related Announcements

PAR-19-040 - Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective immediately, in PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)".

The following text has been added to reflect NIAID's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.855

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

The Chemical Countermeasures Research Program (CCRP) at the NIAID is responsible for the oversight and overall execution of the medical chemical countermeasures against chemical threats initiative across the NIH. To learn more about the CCRP and the NIAID leadership role, see DOI: 10.1002/ddr.21707.
 

Section VII. Agency Contacts

Scientific/Research Contact(s)

Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: [email protected]

Financial/Grants Management Contact(s)

Jason Lundgren
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (240) 669-2973
Email: [email protected]

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: [email protected]